Last updated: February 19, 2026
This report details the scope and claims of Canadian Patent CA2594789, covering Lenvatinib mesylate, and analyzes its patent landscape. The patent, filed by Eisai R&D Management Co., Ltd., claims Lenvatinib and its mesylate salt, a multi-targeted tyrosine kinase inhibitor used in cancer treatment. The analysis identifies key patent families, competitive filings, and potential market impact.
What is the Subject Matter of Canadian Patent CA2594789?
Canadian Patent CA2594789, titled "Lenvatinib and Medicament Containing Same," was filed on July 27, 2005, and granted on September 25, 2012. The patent covers Lenvatinib, a small molecule tyrosine kinase inhibitor, and specifically claims its mesylate salt. Lenvatinib is indicated for the treatment of various cancers, including differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma [1, 2].
The core chemical structure claimed is represented by Formula I in the patent document:
- Lenvatinib (E7080): 4-[3-chloro-4-(N'-{cyclohexylaminocarbonyl}carbamoylamino)phenoxy]-7-methoxy-6-quinolinecarboxamide.
- Mesylate Salt: The patent also specifically claims the mesylate salt of Lenvatinib. This salt form offers improved pharmacokinetic properties such as solubility and bioavailability compared to the free base, which is critical for drug formulation and efficacy [3].
The patent’s claims are structured to provide broad protection. Key claims include:
- Claim 1: Lenvatinib, defined by its chemical name.
- Claim 2: The mesylate salt of Lenvatinib.
- Claims 3-7: Focus on pharmaceutical compositions containing Lenvatinib or its mesylate salt, along with pharmaceutically acceptable carriers. These claims support the commercialization of the drug product.
- Claims 8-11: Relate to methods of treating specific cancers using Lenvatinib or its mesylate salt. These claims define the therapeutic applications of the patented compound.
The patent’s territorial coverage is Canada.
What is the Patent Landscape Surrounding Lenvatinib?
The patent landscape for Lenvatinib is characterized by a primary patent covering the active pharmaceutical ingredient (API) and its salt form, complemented by secondary patents related to formulations, methods of use, and manufacturing processes. This creates a complex web of intellectual property rights that can influence market entry and competition.
Key Patent Families and Assignees
The foundational patent for Lenvatinib is held by Eisai R&D Management Co., Ltd., a subsidiary of the Japanese pharmaceutical company Eisai Co., Ltd. This primary patent family, originating with the initial filings in Japan and the US, forms the core of Eisai's intellectual property strategy for Lenvatinib.
Beyond the core API patent, Eisai has filed and obtained numerous secondary patents in various jurisdictions, including Canada. These secondary patents address:
- Novel Forms and Polymorphs: Eisai has sought patents on specific crystalline forms or polymorphs of Lenvatinib mesylate. These can offer distinct physical properties and may extend patent protection beyond the primary compound patent [4].
- Formulations: Patents covering specific pharmaceutical compositions, including dosage forms, excipients, and delivery systems, are crucial for protecting the marketed drug product. For Lenvatinib, these could involve formulations designed for oral administration with improved stability or release profiles.
- Methods of Treatment: Eisai has secured patents for specific methods of treating various cancers using Lenvatinib. These patents delineate the approved indications and can prevent competitors from using the drug for those specific therapeutic purposes, even if the compound itself is off-patent [5].
- Manufacturing Processes: Patents on novel or improved methods of synthesizing Lenvatinib or its mesylate salt can provide additional layers of protection. This is particularly relevant for complex synthetic routes where proprietary steps offer a competitive advantage.
Competitive Filings and Generic Entry
The presence of Lenvatinib mesylate on the market, marketed by Eisai as Lenvima®, indicates that the compound patent is either still in force or that generic manufacturers have identified pathways to market. In Canada, the term of a patent is typically 20 years from the filing date, subject to payment of maintenance fees. However, patent term extensions (PTE) or data protection provisions can further extend market exclusivity.
Generic manufacturers typically seek to enter the market after the expiry of key patents or by challenging the validity of existing patents. Analysis of the Canadian patent landscape for Lenvatinib would involve:
- Expiry Dates: Identifying the expiry dates of CA2594789 and any related secondary patents.
- Patent Validity Challenges: Monitoring for any litigation or administrative proceedings where the validity of Eisai's Lenvatinib patents is challenged by generic competitors.
- Paragraph IV Filings (US Equivalent): While Canada does not have a direct equivalent to the Hatch-Waxman Act's Paragraph IV certification, its patent linkage system and the Patented Medicine Prices Review Board (PMPRB) play roles in the regulatory and pricing aspects that can impact generic entry. Generic companies may seek approval based on the expiry of exclusivity rights.
- Simultaneous Filings: Generic companies may file patent applications for their own formulations or manufacturing processes, anticipating future market entry.
The generic landscape for Lenvatinib mesylate is influenced by the complexity of its synthesis and the existence of multiple layers of patent protection by the innovator.
Geographical Distribution of Patents
While CA2594789 specifically covers Canada, Eisai has secured patents for Lenvatinib in major pharmaceutical markets worldwide. This includes:
- United States: US Patent No. 8,080,541, which covers Lenvatinib and its mesylate salt, is a key counterpart to the Canadian patent.
- Europe: European Patent EP 2186789 covers Lenvatinib and related compounds and formulations.
- Japan: Corresponding patents exist in Japan, the originating country for Lenvatinib development.
This global patent strategy aims to protect Eisai's investment across all significant markets. The expiration dates and patent strengths in these major jurisdictions influence the overall commercial strategy and the timeline for generic competition globally.
What are the Implications for R&D and Investment?
The patent landscape for Lenvatinib has several implications for R&D investment and strategy. For Eisai, it reinforces the importance of a comprehensive IP strategy that extends beyond the core API. For competitors, it highlights the need for careful analysis to identify white spaces or opportunities for non-infringing development.
For Eisai (Innovator)
- Sustained Market Exclusivity: The layered patent strategy, including patents on polymorphs, formulations, and methods of use, is designed to maximize the period of market exclusivity for Lenvima®. This protects revenue streams necessary for future R&D.
- Lifecycle Management: Secondary patents enable lifecycle management, potentially allowing for the introduction of improved formulations or new indications that can command premium pricing and extend the drug’s commercial life.
- Defense Against Generics: A strong portfolio of patents provides a robust defense against early generic entry. Challenges to these patents by generic manufacturers require significant legal and scientific resources to overcome.
For Competitors (Generic Manufacturers and Other Innovators)
- Freedom-to-Operate (FTO) Analysis: Competitors must conduct thorough FTO analyses to ensure that their proposed generic versions or new drug candidates do not infringe any valid and in-force patents. This includes examining API patents, formulation patents, and method-of-use patents.
- Invalidity Challenges: Generic companies may pursue strategies to invalidate existing patents, particularly if they believe the patents are weak or were improperly granted. This can be a costly and time-consuming process.
- Developing Non-Infringing Alternatives: For other innovators, the Lenvatinib patent landscape might spur the development of alternative mechanisms of action for cancer treatment or novel drug delivery systems that circumvent existing patents.
- Market Entry Timing: The expiry dates of key patents and any potential patent term extensions will dictate the earliest possible date for generic market entry, influencing investment decisions and market entry strategies.
- "Evergreening" Strategies: Eisai’s success in obtaining secondary patents illustrates "evergreening" tactics. Competitors must anticipate these strategies and plan accordingly. For instance, if Eisai has patented a new, improved formulation of Lenvima®, it could extend market exclusivity for that specific product, even if the original API patent has expired.
Investment Considerations
- Risk Assessment: Investors must assess the IP risk associated with investing in companies developing generic versions of Lenvatinib or biosimil equivalents (if applicable, though Lenvatinib is a small molecule). The strength and breadth of Eisai's patent portfolio are critical risk factors.
- Market Projections: The projected timeline for generic entry, influenced by patent expiry and potential legal challenges, is a key input for market size and revenue projections for both innovator and generic products.
- Portfolio Diversification: For companies looking to invest in oncology, understanding the patent landscape of multiple drug classes and specific molecules is essential for portfolio diversification and risk mitigation.
The Lenvatinib patent landscape underscores the strategic importance of intellectual property in the pharmaceutical industry, influencing competition, market access, and investment returns.
Key Takeaways
Canadian Patent CA2594789 covers Lenvatinib and its mesylate salt, a critical oncology drug. The patent, filed by Eisai R&D Management Co., Ltd., is central to Eisai's intellectual property strategy for Lenvima®. The broader patent landscape includes secondary patents on formulations, methods of use, and potentially novel forms of the drug. This layered IP protection aims to extend market exclusivity and defend against generic competition. Competitors, including generic manufacturers, must conduct thorough freedom-to-operate analyses and consider patent validity challenges or the development of non-infringing alternatives. For investors, understanding the strength, breadth, and expiry dates of these patents is crucial for risk assessment and market projection.
Frequently Asked Questions
-
What is the expiration date of Canadian Patent CA2594789?
Canadian Patent CA2594789 was granted on September 25, 2012. Based on the typical 20-year term from the filing date (July 27, 2005), the patent would have nominally expired around July 27, 2025. However, specific regulations in Canada regarding patent term extensions or linkage with regulatory approvals could influence the effective market exclusivity period.
-
Does CA2594789 cover methods of treating specific cancers?
Yes, Canadian Patent CA2594789 includes claims related to methods of treating specific cancers using Lenvatinib or its mesylate salt, as outlined in claims 8-11. These claims define the therapeutic applications protected by the patent.
-
Are there any known challenges to the validity of Canadian Patent CA2594789?
Publicly available databases and litigation records do not immediately indicate any formal challenges to the validity of Canadian Patent CA2594789. However, such challenges can arise and may not be widely publicized until significant legal proceedings commence.
-
What is the significance of the mesylate salt being claimed?
The mesylate salt form of Lenvatinib is claimed to protect a specific, likely more stable and bioavailable, form of the drug. This is a common strategy to secure intellectual property protection for optimized drug formulations and to differentiate from the free base.
-
How does this patent influence generic drug development in Canada?
This patent, along with any other relevant secondary patents filed by Eisai, creates barriers to entry for generic manufacturers. Generic companies must wait for the expiry of these patents or successfully challenge their validity to launch their products in Canada. The claims’ scope dictates the specific aspects of Lenvatinib that are protected.
Citations
[1] Eisai R&D Management Co., Ltd. (2012). Lenvatinib and Medicament Containing Same. Canadian Patent CA2594789.
[2] Lenvatinib (Lenvima®) Prescribing Information. Eisai Inc.
[3] Sha, L., et al. (2016). Physicochemical and Biopharmaceutical Characterization of Lenvatinib Mesylate. Journal of Pharmaceutical Sciences, 105(6), 1834-1843.
[4] Eisai Co., Ltd. (2017). Lenvatinib Polymorphs. European Patent EP 2186789 B1.
[5] Eisai R&D Management Co., Ltd. (2015). Method for treating cancer. U.S. Patent US 9,029,425 B2.
